top of page
CaresLinx Pro Series

CareLink의 차세대 신장질환 치료제

"신장질환 치료의 패러다임을 바꾸는 새로운 가능성."

CareLink의 치료제는 기존 신장질환 치료제의 한계를 극복하고, 근본적인 치료가 가능하도록 개발되고 있습니다.

Original Technology​​​​
원천 기술 소개

​​

  • We specialise in the design, development and production of probe cards.

  • We are the second largest manufacturer of probe cards in the world in terms of volume and turnover.​

원천 기술
임상 결과
Clinical Trial Results
Definition

​​

  • Derived from Latin word “aptus” which means “perfectly suited”

  • Oligonucleotides (20~60 nucleotides, DNA or RNA)

  • Targeted molecules varies. It is from small particles to proteins.

  • High Affinity(affinity, Kd= nM~pM) and Specificity(Kd/Kd'=~10-5)

  • Affinity is 1000 times higher than antibodies and antigens, leading to recognition as a new drug candidate.

관련 특허
관련 특허
Description

​​

  • Derived from Latin word “aptus” which means “perfectly suited”

  • Oligonucleotides (20~60 nucleotides, DNA or RNA)

  • Targeted molecules varies. It is from small particles to proteins.

  • High Affinity(affinity, Kd= nM~pM) and Specificity(Kd/Kd'=~10-5)

  • Affinity is 1000 times higher than antibodies and antigens, leading to recognition as a new drug candidate.

Need more details? Contact us

We are here to assist. Contact us by phone, email or via our Social Media channels.

CareLink Co., Ltd.

Address :, Republic of Korea

Tel : +82-123-1234        / Fax : +82-123-1234         

Email : info@CaresLinkx.com

​

Copyright©2022 CareLink All Rights Reserved.

bottom of page